Freenome Stock
Multiomics Platform for Early Disease Screening
Sign up today and learn more about Freenome Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Freenome Stock
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Investors
Andreessen Horowitz
Lyft, Robinhood, Databricks, Airbnb, Instacart, Stripe, Magic Leap, Rappi, CoinSwitch Kuber, Devoted Health
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Funding History
October 2015 | $800K |
---|---|
June 2016 | $5.6M |
August 2017 | $72.0M |
June 2019 | $165M |
July 2020 | $270M |
Management
Chief Executive Officer
Mike Nolan
Chief Financial Officer
William Quirk
Press
news - Mar, 5 2024
The 10 Biggest Rounds Of February: Epic Games Leads The List Thanks To House Of Mouse Investmentvator - Feb, 28 2024
Freenome scores $254M to advance its cancer-detection blood testsvcnewsdaily - Feb, 23 2024
Freenome Lands $254Mbioworld - Feb, 23 2024
Freenome liberated with $254M infusion for cancer testing